Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study-Reference-Cited by-同舟云学术

Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study

Published:2018-12 Issue:12 Volume:13 Page:1906-1918
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Gandara David R.,von Pawel Joachim,Mazieres Julien,Sullivan Richard,Helland Åslaug,Han Ji-Youn,Ponce Aix Santiago,Rittmeyer Achim,Barlesi Fabrice,Kubo Toshio,Park Keunchil,Goldschmidt Jerome,Gandhi Mayank,Yun Cindy,Yu Wei,Matheny Christina,He Pei,Sandler Alan,Ballinger Marcus,Fehrenbacher Louis

Funder

Roche

Amgen

Roche/Genentech

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference33 articles.

1. Molecular pathways: next-generation immunotherapy—inhibiting programmed death-ligand 1 and programmed death-1;Chen;Clin Cancer Res,2012

2. Predictive correlates of response to the anti–PD-L1 antibody MPDL3280A in cancer patients;Herbst;Nature,2014

3. MPDL3280A (anti–PD-L1) treatment leads to clinical activity in metastatic bladder cancer;Powles;Nature,2014